Recent review articles about breast cancer (InTextoResearch)

InTextoResearch, scientific information agency


InTextoResearch informs on the last review articles in the field of
breast cancer:


The endothelin axis: a novel target for pharmacotherapy of female
malignancies.
Smollich M, Wulfing P.
Curr Vasc Pharmacol. 2007 Jul;5(3):239-48.

Clinical practice. Management of an inherited predisposition to breast
cancer.
Robson M, Offit K.
N Engl J Med. 2007 Jul 12;357(2):154-62.

Trastuzumab--mechanism of action and use in clinical practice.
Hudis CA.
N Engl J Med. 2007 Jul 5;357(1):39-51.

DNA methylation markers: a versatile diagnostic tool for routine
clinical use.
Lesche R, Eckhardt F.
Curr Opin Mol Ther. 2007 Jun;9(3):222-30.

Morphological detection of hormone and growth factor receptors in
breast cancer.
Kolble K.
Recent Results Cancer Res. 2007;176:201-9.

Proteomic expression profiling of breast cancer.
Neubauer H, Fehm T, Schutz C, Speer R, Solomayer E, Schrattenholz A,
Cahill MA, Kurek R.
Recent Results Cancer Res. 2007;176:89-120.

Clinical inquiries. Does a low-fat diet help prevent breast cancer?
Steiner E, Klubert D, Hayes M, Hamilton A, Kolasa K.
J Fam Pract. 2007 Jul;56(7):583-4.

Novel enhanced delivery taxanes: an update.
Perez EA
Semin Oncol. 2007 Jun;34(3):suppl 1-5.

Risk factors and hormone-receptor status: epidemiology, risk-
prediction models and treatment implications for breast cancer.
Chen WY, Colditz GA.
Nat Clin Pract Oncol. 2007 Jul;4(7):415-23.

Breast cancer diagnosed during pregnancy.
Bodner-Adler B, Bodner K, Zeisler H.
Anticancer Res. 2007 May-Jun;27(3B):1705-7.

The potential clinical applications of insulin-like growth factor-1
ligand in human breast cancer.
Chong YM, Subramanian A, Sharma AK, Mokbel K.
Anticancer Res. 2007 May-Jun;27(3B):1617-24.

Aromatase inhibitors in post-menopausal metastatic breast carcinoma.
Carlini P, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Ruggeri
EM, Milella M, Nuzzo C, Cecere FL, Gelibter A, Pino MS, Nistico C,
Cuppone F, Metro G, Terzoli E, Cognetti F, Ferretti G.
Expert Opin Investig Drugs. 2007 Jul;16(7):1023-36.

EGFR and HER-2 antagonists in breast cancer.
O'Donovan N, Crown J.
Anticancer Res. 2007 May-Jun;27(3A):1285-94.

PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-
positive early breast cancer.
Metcalfe S, Evans J, Priest G.
N Z Med J. 2007 Jun 15;120(1256):U2593.

Smad4-independent TGF-beta signaling in tumor cell migration.
Giehl K, Imamichi Y, Menke A.
Cells Tissues Organs. 2007;185(1-3):123-30.

CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast
cancer.
Kleer CG, Zhang Y, Merajver SD.
Cells Tissues Organs. 2007;185(1-3):95-9.

Beta-catenin/LEF-1 signalling in breast cancer--central players
activated by a plethora of inputs.
Gebeshuber CA, Sladecek S, Grunert S.
Cells Tissues Organs. 2007;185(1-3):51-60.

Management of benign tumors of the adolescent breast.
Chang DS, McGrath MH.
Plast Reconstr Surg. 2007 Jul;120(1):13e-19e.

Highly active anticancer curcumin analogues.
Mosley CA, Liotta DC, Snyder JP.
Adv Exp Med Biol. 2007;595:77-103.

Clinical practice. Follow-up of patients with early breast cancer.
Hayes DF
N Engl J Med. 2007 Jun 14;356(24):2505-13.

What progress have we made in managing inflammatory breast cancer?
Dawood S, Cristofanilli M.
Oncology (Williston Park). 2007 May;21(6):673-9

Screening, prevention, detection, and treatment of cancer therapy-
induced bone loss in patients with breast cancer.
Limburg CE.
Oncol Nurs Forum. 2007 Jan;34(1):55-63.

Surgical management of breast cancer.
Vazquez B, Rousseau D, Hurd TC.
Semin Oncol. 2007 Jun;34(3):234-40.

Management strategies for pain in breast carcinoma patients: current
opinions and future perspectives.
Saxena AK, Kumar S.
Pain Pract. 2007 Jun;7(2):163-77.


(InTextoResearch contact: Marc Lacroix, Baelen, Wallonia, Belgium -
scimedweb@xxxxxxxx)

.

Loading